Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller

Journal of the National Cancer Institute

Volumn 105, Issue 16, 2013, Pages 1212-1220

  Nitadori, Jun Ichi ^a,d   Bograd, Adam J ^a,b   Kadota, Kyuichi ^a   Sima, Camelia S ^c   Rizk, Nabil P ^a   Morales, Eduardo A ^a   Rusch, Valerie W ^a   Travis, William D ^a   Adusumilli, Prasad S ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Center for Cell Engineering   (United States)

^c Department of Epidemiology and Biostatistics ^*  (United Kingdom)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LOCAL RECURRENCE FREE SURVIVAL; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WEDGE RESECTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PNEUMONECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84883185369     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt166     Document Type: Article

References (40)

1. Rusch VW, Hawes D, Decker PA, et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011;29(32):4313-4319.
2. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60(3):615-622.
3. Devesa SS, Bray F, Vizcaino A P, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117(2):294-299.
4. Curado MP, Edwards B, Shin HR. Cancer Incidence in Five Continents. Vol. IX. IARC Scientific Publications No. 160. Lyon: IARC; 2007.
5. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
6. Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. 2005;129(1):87-93.
7. Koike T, Yamato Y, Yoshiya K, et al. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg. 2003;125(4):924-928.
8. Yoshikawa K, Tsubota N, Kodama K, et al. Prospective study of extended segmentectomy for small lung tumors: the final report. Ann Thorac Surg. 2002;73(4):1055-1058; discussion 1058-1059.
9. Wisnivesky J P, Henschke CI, Swanson S, et al. Limited resection for the treatment of patients with stage IA lung cancer. Ann Surg. 2010;251(3):550-554.
10. Kates M, Swanson S, Wisnivesky J P. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer ≤1 cm in size: a review of SEER data. Chest. 2011;139(3):491-496.
11. Keenan RJ, Landreneau RJ, Maley RH Jr, et al. Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg. 2004;78(1):228-233.
12. Suzuki K, Koike T, Asakawa T, et al. A prospective radiological study of thin-section computed tomography to predict pathological noninva-siveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol. 2011;6(4):751-756.
13. Kadota K, Colovos C, Suzuki K, et al. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol. 2012;19(11):3598-3605.
14. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-285.
15. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653-664.
16. Yoshizawa A, Sumiyoshi S, Moreira AL, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma (ADC) classification and use of comprehensive histologic subtyping (CHS) for architectural grading in 432 Japanese patients. Mod Pathol. 2011;24 (suppl 1s):429a.
17. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarci-noma is a stage-independent predictor of survival. J Clin Oncol. 2012;30(13): 1438-1446.
18. Gu J, Lu C, Guo J, et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-a single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol. 2013;107(5):474-480.
19. Travis WD BE, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
20. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706-714.
21. Yoshida J, Nagai K, Asamura H, et al. Visceral pleura invasion impact on non-small cell lung cancer patient survival: its implications for the forthcoming TNM staging based on a large-scale nation-wide database. J Thorac Oncol. 2009;4(8):959-963.
22. Travis WD, Brambilla E, Rami-Porta R, et al. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008;3(12):1384-1390.
23. Donington J, Ferguson M, Mazzone P, et al. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest. 2012;142(6):1620-1635.
24. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740-801.
25. Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012;18(8):2301-2308.
26. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
27. Fine J P, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
28. Maeda R, Isowa N, Onuma H, et al. Lung adenocarcinomas with micro-papillary components. Gen Thorac Cardiovasc Surg. 2009;57(10):534-539.
29. Tsutsumida H, Nomoto M, Goto M, et al. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol. 2007;20(6):638-647.
30. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol. 2003;27(1):101-109.
31. Amin MB, Tamboli P, Merchant SH, et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol. 2002;26(3):358-364.
32. Kamiya K, Hayashi Y, Douguchi J, et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarci-noma. Mod Pathol. 2008;21(8):992-1001.
33. Makimoto Y, Nabeshima K, Iwasaki H, et al. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (
34. Nagano T, Ishii G, Nagai K, et al. Structural and biological properties of a papillary component generating a micropapillary component in lung adenocarcinoma. Lung Cancer. 2010;67(3):282-289.
35. Colonias A, Betler J, Trombetta M, et al. Mature follow-up for high-risk stage I non-small-cell lung carcinoma treated with sublobar resection and intraoperative iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2011;79(1):105-109.
36. Santos R, Colonias A, Parda D, et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with stage I non-small-cell lung cancer. Surgery. 2003;134(4):691-697; discussion 697
37. d'Amato TA, Galloway M, Szydlowski G, et al. Intraoperative brachyther-apy following thoracoscopic wedge resection of stage I lung cancer. Chest. 1998;114(4):1112-1115.
38. Fernando HC, Santos RS, Benfield JR, et al. Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;129(2):261-267.
39. Miller JI, Hatcher CR Jr. Limited resection of bronchogenic carcinoma in the patient with marked impairment of pulmonary function. Ann Thorac Surg. 1987;44(4):340-343.
40. Smith R P, Schuchert M, Komanduri K, et al. Dosimetric evaluation of radiation exposure during I-125 vicryl mesh implants: implications for ACOSOG z4032. Ann Surg Oncol. 2007;14(12):3610-3613.